Valeant Pharmaceuticals reported $369M in Interest Expense on Debt for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Amgen AMGN:US $ 281M 4M
Ani Pharmaceuticals ANIP:US $ 2.53M 77K
Aphria Inc APH:CN C$ 10.45M 3.97M
Aurora Cannabis Inc ACB:CN 15.88M 1.11M
Biogen BIIB:US $ 66.3M 9.9M
Bristol Myers Squibb BMY:US $ 330M 23M
Canopy Growth Corp WEED:CN C$ 24.56M 19.81M
Catalent CTLT:US $ 31.9M 5M
Danaher DHR:US $ 62M 0M
Drreddys Laboratories RDY:US $ 193M 104M
Endo International Ordinary Shares ENDP:US $ 141.64M 6.95M
Gilead Sciences GILD:US $ 256M 1M
Gw Pharmaceuticals GWPH:US $ 0.29M 0.02M
JAZZ PHA JAZZ:US $ 69.82M 41.24M
Lannett LCI:US $ 13.22M 0.59M
Nektar Therapeutics NKTR:US $ 13.09M 0.21M
Pacira Pharmaceuticals PCRX:US $ 7.02M 0.05M
Phibro Animal Health PAHC:US $ 3.03M 0.05M
Prestige Brands PBH:US $ 15.08M 3.91M
Revance Therapeutics RVNC:US $ 1.57M 9K
Supernus Pharmaceuticals SUPN:US $ 5.47M 0.4M
Valeant Pharmaceuticals VRX:CN $ 369M 5M
Vertex Pharmaceuticals VRTX:US $ 15.48M 0.2M
Zoetis ZTS:US $ 57M 0M